Upadacitinib

📢 Discover the key takeaways from the PBAC December 2023 meeting and their potential impact on the future of #PharmaceuticalTreatments. Explore the decisions on new drug listings, changes to existing ones, and deferred decisions. 📊💊 #PBACMeetingOutcomes #HealthcareIndustry. Click the link to read more! 🔗

Treatment guidelines for adults with active non-radiographic axial spondyloarthritis recommend the use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Tumor Necrosis Factor-alpha (TNF-alpha) inhibitors. If these first-line treatments don’t work or aren’t suitable, doctors may consider secukinumab or ixekizumab (IL-17 inhibitors). Clinical trials show that upadacitinib, an oral Janus Kinase (JAK) inhibitor, can reduce symptoms and improve the quality of life in Spondyloarthritis (SpA) patients. This effectiveness rivals that of biologics. Clinicians use the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) […]